Media headlines about Foundation Medicine (NASDAQ:FMI) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2285255117937 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have impacted Accern’s scoring:
- Foundation Medicine Inc (FMI) COO Sells $338,183.18 in Stock (americanbankingnews.com)
- Foundation Medicine Inc (FMI) Director Evan/ Fa Jones Sells 6,500 Shares (americanbankingnews.com)
- Foundation Medicine Inc (FMI) CFO Jason Ryan Sells 21,726 Shares (americanbankingnews.com)
- Foundation Medicine Inc (FMI) Insider Vincent A. Miller Sells 20,000 Shares (americanbankingnews.com)
- Foundation Medicine (FMI) Upgraded to Buy at Zacks Investment Research (americanbankingnews.com)
Shares of Foundation Medicine (NASDAQ:FMI) opened at $62.25 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03. Foundation Medicine has a 1 year low of $17.10 and a 1 year high of $70.75.
Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings data on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.16. The company had revenue of $42.66 million for the quarter, compared to analyst estimates of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The firm’s revenue for the quarter was up 45.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.90) EPS. equities analysts expect that Foundation Medicine will post -4.44 EPS for the current year.
Several brokerages have recently issued reports on FMI. Zacks Investment Research cut shares of Foundation Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Saturday, September 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $45.33.
In other Foundation Medicine news, COO Steven J. Kafka sold 3,201 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $38.80, for a total value of $124,198.80. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Jason Ryan sold 21,726 shares of the stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $61.26, for a total transaction of $1,330,934.76. Following the transaction, the chief financial officer now owns 55,639 shares in the company, valued at $3,408,445.14. The disclosure for this sale can be found here. Insiders sold a total of 84,057 shares of company stock worth $4,588,768 over the last 90 days. Insiders own 2.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2017/12/08/foundation-medicine-fmi-getting-somewhat-positive-press-coverage-report-finds-updated-updated.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.